Merck & Co., Inc.
$398.76B- Market cap
- $363.98B
- Debt
- +$49.34B
- Cash
- −$14.57B
Capital structure 88% equity / 12% debt · EV / Revenue 6.13x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MRK stock price near parity vs REGN $147.53 current versus $141.75 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at REGN's multiple
Implied fair value · at MRK's multiple
Snapshot Sep 9, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 88% equity / 12% debt · EV / Revenue 6.13x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Merck & Co., Inc. · implied price per share
Bear
$56.95
Base
$70.71
Bull
$89.28
REGENERON PHARMACEUTICALS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MRK can sustain its high margins and modest growth while improving quality signals, then hold rather than add aggressively because the stock already trades above REGN-implied range and above the DCF midpoint on the data provided.
MRK trades above REGN-implied valuation range, with current price $119.52 versus implied price $107.29, suggesting about 10.2% downside. The stock is also near the upper end of REGN implied range and below the top of its historical band, so the market is not paying a full historical premium but is still above the relative valuation benchmark.
Supporting Metrics